Funding of Ebiox Subsidiary
June 05 2009 - 2:00AM
UK Regulatory
TIDMHCEG
RNS Number : 4170T
Healthcare Enterprise Group PLC
05 June 2009
Healthcare Enterprise Group plc
("HCEG", "the Company" or "the Group")
Funding of Ebiox subsidiary
Healthcare Enterprise Group plc (AIM: HCEG), announces that on 1st June 2009
it's 95% owned subsidiary Ebiox Limited ("Ebiox") received applications to
subscribe for shares in Ebiox amounting to GBP700,000 in cash before expenses.
The new investors will account for approximately 36.8% of the increased share
capital of Ebiox. Of the total amount subscribed, GBP400,000 (21.1%) has been
subscribed by interests associated with Mr. Nigel Wray and GBP50,000 (2.6%) has
been subscribed by Mr. John Honey, Ebiox's Executive Chairman. A further
GBP250,000 (13.1%) is conditional on shareholder approval of the
investing company and is expected to complete by the end of June 2009. Mr. Wray
and Mr. Honey will also be entitled to warrants to subscribe for an additional
53,333 and 6,667 shares respectively in Ebiox at GBP1.00 per share for
the period ending 1st June 2012. Mr. Wray will also be joining the board of
Ebiox as a non executive director.
Of the proceeds, the sum of GBP100,000 has been paid to HCEG in the form of
management fees to fund short term operating costs. The balance of the proceeds
will leave Ebiox fully funded for the short and medium term.
Ebiox has witnessed a surge in demand following the outbreak of swine flu, and
the Ebiox management, headed by John Honey, has been keen to take advantage of
the flow of new orders. Accordingly, the Ebiox board considered that the best
way for the company to raise new funds while its parent HCEG was still
finalising its own restructuring, was to raise capital directly. It is hoped
that with this injection of new funds, and the introduction of Mr. Wray to the
board, Ebiox will be able to seize this opportunity to create additional sales
and negotiate additional products, such as those which have now been contracted
to Great Ormond Street Hospital under the Ebiox brand.
As set out in the announcement of 29 May 2009, the Group is currently engaged in
a process of refinancing whereby it is proposed that certain significant
liabilities, including convertible unsecured loan stock, held in HCEG will be
converted into a combination of equity in HCEG, shares in the company's
investment in First Aid Holdings Limited and subsidiaries Ebiox and Reproductive
Sciences Limited ("RSL").
"In the future, the Group expects to function as an investment holding company
with a minimal cost base which will be funded through a small-fund raising or
further realisation of the Group's investments. Notwithstanding the current
economic climate, we remain convinced that Healthcare Enterprise Group has
valuable investments in exciting niches of the healthcare market."
Whilst this Ebiox funding has provided some additional working capital for the
Group's immediate needs, discussions continue with a small group of investors to
raise additional capital for the Group. Whilst these discussions have yet to
reach a conclusion, the directors remain confident that further funds will be
raised although there can be no guarantee that such funds will be secured. In
the event that these discussions are not successfully concluded in the next
month, the Group's funding position will be such that it will be required to
consider a range of alternatives including further sales of shares in its
investee companies. If the Company is unable to raise sufficient cash from such
sales, the Directors may have no alternative but to consider whether it is
appropriate for the Group to remain as a going concern.
Pursuant to the announcement made on 22 December 2008, the Company's shares
remain suspended from trading on AIM.
Further Enquiries:
Healthcare Enterprise Group Plc
Lyndon Gaborit, Executive Deputy Chairman Tel: + 44 (0)1925 898 201
www.hcegroup.com
Daniel Stewart & Company Plc
Tel 020 7776 6550
Graham Webster/Stewart Dick
Notes to Editor:
Healthcare Enterprise Group PLC companies include Ebiox Limited, a specialist
disinfectant and decontamination company which has a range of proprietary
products patented and approved for sale in multiple world markets; Reproductive
Sciences Limited which invests in medical devices product development,
particularly in the area of women's' health; and investments in healthcare
products and services.
Nigel Wray has extensive experience as an investor in both quoted and unquoted
companies. He is the Chairman of Saracens Rugby Club and British Seafood Group
Holdings Limited, Non-Executive Director of Prestbury Investment Holdings
Limited, Dominos UK & IRL PLC, Play Holdings Limited, Networkers International
Plc, English Wines Group PLC, Seymour Pierce Holdings Limited and several other
private companies.
John Honey, Executive Chairman of Ebiox Limited, brings a wealth of experience
in the disinfectant and decontamination industry as well as senior management
roles in marketing and general management. John previously served as Senior Vice
President of Reckitt Benckiser plc, responsible at various times during his 29
year tenure as executive responsible for Reckitt's global cleaning and
disinfectant businesses, including Dettol, Lysol and Cilit Bang brands and its
worldwide over the counter business which included Boots Healthcare
International (which was acquired for GBP1.9Bn). He retired from Reckitt's in
2007 to pursue private interests.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDGGGVVDLGLZM
Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From Apr 2024 to May 2024
Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From May 2023 to May 2024